Physician profile
Miten Patel
NPI 1891878146
$3,856.36
in general payments reported to CMS, 2019-2025
65 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $197 · 2021: $266 · 2022: $728 · 2023: $722 · 2024: $990 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.91 |
| Education | $272.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $500.36 | 2019-2025 | |
| Janssen Biotech, INC. | $331.91 | 2019-2025 | Darzalex, Imbruvica, Talvey |
| Astellas Pharma US INC | $245.24 | 2019-2025 | Xtandi |
| Beigene USA, INC. | $188.31 | 2022-2023 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $184.86 | 2021-2023 | |
| Daiichi Sankyo INC. | $142.00 | 2019-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $130.67 | 2022-2023 | Reblozyl |
| Inari Medical, INC. | $123.02 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $116.32 | 2022-2025 | |
| Eisai INC. | $103.25 | 2022-2025 | |
| Macrogenics, INC. | $93.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.81 | 2019-2025 | Gilotrif |
| Merck Sharp & Dohme LLC | $90.22 | 2019-2024 | Keytruda, Welireg, Reblozyl |
| Genzyme Corporation | $89.47 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $78.95 | 2021-2025 | Onivyde, Somatuline Depot |
Show all 64 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miten Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.